TOULOUSE, France & FULLERTON, Calif.–(BUSINESS WIRE)–Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible for the PEA PME), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I technology platform, today announced a strategic manufacturing partnership with OLON, a global CDMO, to support the next stage of development and commercialization of CER-001. Preparing CER-001 for the transition from developm